Entrada Therapeutics Inc (TRDA)
14.32
+0.07
(+0.49%)
USD |
NASDAQ |
Jul 01, 16:00
14.30
-0.02
(-0.14%)
After-Hours: 20:00
Entrada Therapeutics Cash from Operations (Quarterly): -25.52M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -25.52M |
| December 31, 2023 | -4.013M |
| September 30, 2023 | -24.49M |
| June 30, 2023 | -35.09M |
| March 31, 2023 | 203.40M |
| December 31, 2022 | -27.30M |
| September 30, 2022 | -27.48M |
| Date | Value |
|---|---|
| June 30, 2022 | -18.01M |
| March 31, 2022 | -20.99M |
| December 31, 2021 | -20.54M |
| September 30, 2021 | -14.08M |
| June 30, 2021 | -7.91M |
| March 31, 2021 | -8.336M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-35.09M
Minimum
Jun 2023
203.40M
Maximum
Mar 2023
-2.336M
Average
-20.54M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 31.92M |
| Vertex Pharmaceuticals Inc | 1.307B |
| Sarepta Therapeutics Inc | -242.08M |
| PTC Therapeutics Inc | 70.76M |
| GlycoMimetics Inc | -10.51M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 26.15M |
| Cash from Financing (Quarterly) | 0.206M |
| Free Cash Flow | -93.90M |
| Free Cash Flow Per Share (Quarterly) | -0.7576 |
| Free Cash Flow to Equity (Quarterly) | -26.36M |
| Free Cash Flow to Firm (Quarterly) | -26.36M |
| Free Cash Flow Yield | -19.30% |